Slingshot members are tracking this event:

AbbVie Receives Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
- DIPG are highly aggressive and difficult to treat brain tumors found at the base of the brain 
- Marks the first FDA Rare Pediatric Designation for an AbbVie investigational medicine 
- In 2014, the FDA and European Medicines Agency granted ABT-414 Orphan Drug Designation for the treatment of glioblastoma and glioma in adults, respectively
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 11, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Abt-414, Diffuse Intrinsic Pontine Glioma, Pediatric Brain Tumor